Find Research Studies in Michigan for Allergies

Condition:   Asthma
Interventions:   Biological: Mepolizumab;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Inner-City Asthma Consortium;   GlaxoSmithKline
Not yet recruiting

Conditions:   Asthma;   Allergic Asthma;   Allergies;   Healthy
Intervention:  
Sponsors:   University of Wisconsin, Madison;   National Institutes of Health (NIH)
Not yet recruiting

Condition:   Atopic Dermatitis
Intervention:   Drug: INCB018424 phosphate cream
Sponsor:   Incyte Corporation
Recruiting

Condition:   Eosinophilic Esophagitis
Interventions:   Drug: APT-1011;   Drug: Placebo
Sponsor:   Adare Pharmaceuticals, Inc.
Recruiting

Condition:   Asthma
Interventions:   Drug: Benralizumab (Medi-563);   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting

Condition:   Psoriasis
Intervention:   Other: 12-week elimination diet
Sponsor:   University of Michigan
Recruiting

Conditions:   Atopic Dermatitis;   Eczema, Atopic
Interventions:   Drug: ALX-101 Gel 1.5% and ALX-101 Gel Vehicle;   Drug: ALX-101 Gel 5% and ALX-101 Gel Vehicle
Sponsor:   Ralexar Therapeutics, Inc.
Recruiting

Condition:   Atopic Dermatitis
Interventions:   Drug: Tralokinumab;   Drug: Placebo
Sponsor:   LEO Pharma
Recruiting

Condition:   Asthma
Intervention:   Behavioral: Multi-Component Technology Based Intervention
Sponsors:   Wayne State University;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Carcinoma
Interventions:   Drug: ribociclib;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   University of Michigan Cancer Center
Recruiting

Condition:   Atopic Dermatitis
Interventions:   Drug: Tralokinumab;   Drug: Placebo
Sponsor:   LEO Pharma
Recruiting

Condition:   Peanut Allergy
Intervention:   Biological: AR101
Sponsor:   Aimmune Therapeutics, Inc.
Recruiting

Condition:   Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Intervention:   Drug: OLAPARIB
Sponsor:   AstraZeneca
Recruiting

Conditions:   Acute Coronary Syndrome;   Chest Pain
Interventions:   Procedure: Blood Sample;   Behavioral: HEART Score
Sponsors:   University of Florida;   Roche Diagnostics
Recruiting

Condition:   Atopic Dermatitis
Interventions:   Drug: INCB018424 cream;   Drug: Triamcinolone 0.1% cream;   Drug: Vehicle cream
Sponsor:   Incyte Corporation
Recruiting

Conditions:   Pruritus;   Atopic Dermatitis
Interventions:   Drug: Serlopitant High Dose;   Drug: Placebo Oral Tablet;   Drug: Serlopitant Low Dose
Sponsor:   Menlo Therapeutics Inc.
Recruiting

Condition:   Asthma
Interventions:   Drug: Dupilumab;   Other: Placebo;   Drug: Asthma Controller Therapies (incl. prednisone/prednisolone);   Drug: Asthma Reliever Therapies
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting

Conditions:   Asthma;   Healthy
Intervention:  
Sponsors:   University of Michigan;   National Institutes of Health (NIH)
Recruiting

Condition:   Asthma
Interventions:   Drug: Fluticasone furoate;   Drug: Placebo;   Drug: Montelukast;   Drug: Short Acting Beta 2 Agonist
Sponsor:   GlaxoSmithKline
Recruiting

Condition:   Prostatic Neoplasms
Interventions:   Drug: BAY1841788 / darolutamide (ODM-201);   Drug: Standard ADT (androgen deprivation therapy);   Drug: Docetaxel;   Drug: Placebo
Sponsors:   Bayer;   Orion Corporation, Orion Pharma
Recruiting

Conditions:   Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions:   Drug: Chemotherapy;   Drug: Rucaparib
Sponsors:   Clovis Oncology, Inc.;   Foundation Medicine
Recruiting

Conditions:   Myelodysplastic Syndrome (MDS);   Chronic Lymphocytic Leukemia (CLL);   Chemotherapy-sensitive Lymphoma;   Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma;   Acute Myelogenous Leukemia (AML);   Acute Biphenotypic Leukemia (ABL);   Acute Undifferentiated Leukemia (AUL)
Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5;   Radiation: Total Body Irradiation (TBI) 200cGy on Day -1;   Procedure: Infusion of non-T-cell depleted bone marrow on Day 0;   Drug: Busulfan;   Drug: Cyclophosphamide 50mg/kg/day IV on Days -2,-1;   Drug: Cyclophosphamide 50mg/kg/day IV on Days -5,-4;   Radiation: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1;   Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4;   Drug: Sirolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Drug: Pre-HCT Mesna on Days -6 and -5;   Drug: Pre-HCT Mesna on Days -2 and -1;   Drug: Pre-HCT Mesna on Days -5 and -4;   Drug: Post-HCT Mesna
Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program;   Resource for Clinical Investigation in Blood and Marrow Transplantation
Recruiting

Conditions:   Asthma;   COPD;   Chronic Obstructive Pulmonary Disease
Interventions:   Procedure: Blood draw;   Procedure: Urine;   Procedure: Lung function measurements;   Procedure: Fractional Exhaled Nitric Oxide (FENO)
Sponsors:   AstraZeneca;   Parexel
Recruiting

Condition:   Eosinophilic Esophagitis (EoE)
Interventions:   Drug: Oral Budesonide Suspension (OBS);   Drug: Placebo
Sponsor:   Shire
Recruiting

Condition:   Metastatic Hormone Sensitive Prostate Cancer
Interventions:   Drug: Enzalutamide;   Drug: Placebo
Sponsors:   Astellas Pharma Global Development, Inc.;   Medivation, Inc.
Recruiting

Condition:   Eosinophilic Esophagitis (EoE)
Interventions:   Drug: OBS;   Drug: Placebo
Sponsor:   Shire
Recruiting

Condition:   Asthma
Interventions:   Drug: QAW039;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Recruiting

Condition:   Asthma
Intervention:  
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Inner-City Asthma Consortium
Recruiting

Conditions:   BRCA Rearrangement;   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Endometrial Undifferentiated Carcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Tumor;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Tumor;   Ovarian Transitional Cell Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions:   Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
Sponsors:   National Cancer Institute (NCI);   AstraZeneca
Recruiting

Condition:   Rhinitis, Allergic, Seasonal
Interventions:   Biological: MK-3641;   Biological: Placebo;   Drug: Self-injectable epinephrine;   Drug: Albuterol/Salbutamol;   Drug: Loratadine;   Drug: Olopatadine;   Drug: Mometasone furoate monohydrate
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting

Conditions:   Hormone Sensitive Prostate Cancer;   Prostate Cancer;   Cancer of the Prostate
Interventions:   Drug: Enzalutamide;   Drug: Placebo;   Drug: Leuprolide
Sponsors:   Pfizer;   Astellas Pharma Inc;   Medivation, Inc.
Recruiting

Condition:   Platinum-Sensitive Ovarian Cancer in First Relapse
Interventions:   Drug: Farletuzumab;   Drug: Placebo
Sponsors:   Morphotek;   Eisai Co., Ltd.
Recruiting

Condition:   Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions:   Drug: OLAPARIB;   Drug: Single agent chemotherapy
Sponsors:   AstraZeneca;   Myriad Genetic Laboratories, Inc.
Recruiting

Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   Philadelphia Chromosome Positive;   Recurrent Adult Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions:   Biological: Blinatumomab;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Prednisone;   Drug: Vincristine Sulfate
Sponsor:   National Cancer Institute (NCI)
Recruiting

Condition:   Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Interventions:   Drug: APR-246;   Drug: Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Sponsor:   Aprea Therapeutics AB
Recruiting

Conditions:   Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Drug: enzalutamide;   Drug: bicalutamide;   Procedure: orchiectomy;   Drug: leuprolide acetate;   Drug: goserelin acetate;   Other: laboratory biomarker analysis
Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting

Condition:   Obesity
Intervention:   Other: Exercise
Sponsors:   University of Michigan;   American Diabetes Association
Recruiting

Conditions:   Ovarian Neoplasms;   Peritoneal Neoplasms;   Fallopian Tube Neoplasms
Interventions:   Drug: Trabectedin;   Drug: DOXIL;   Drug: Dexamethasone
Sponsors:   Janssen Research & Development, LLC;   PharmaMar
Recruiting

Condition:   Obesity
Intervention:  
Sponsors:   University of Michigan;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting